PL374536A1 - Związki heterocykliczne podstawione pirydylem do stosowania w leczeniu lub zapobieganiu infekcji HCV - Google Patents

Związki heterocykliczne podstawione pirydylem do stosowania w leczeniu lub zapobieganiu infekcji HCV

Info

Publication number
PL374536A1
PL374536A1 PL03374536A PL37453603A PL374536A1 PL 374536 A1 PL374536 A1 PL 374536A1 PL 03374536 A PL03374536 A PL 03374536A PL 37453603 A PL37453603 A PL 37453603A PL 374536 A1 PL374536 A1 PL 374536A1
Authority
PL
Poland
Prior art keywords
treating
hcv infection
pyridyl substituted
substituted heterocycles
preventing hcv
Prior art date
Application number
PL03374536A
Other languages
English (en)
Inventor
Rajinder Singh
Dane Goff
John Partridge
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of PL374536A1 publication Critical patent/PL374536A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03374536A 2002-08-23 2003-08-22 Związki heterocykliczne podstawione pirydylem do stosowania w leczeniu lub zapobieganiu infekcji HCV PL374536A1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40546702P 2002-08-23 2002-08-23
US41783702P 2002-10-11 2002-10-11
US47137303P 2003-05-15 2003-05-15
US10/646,348 US7157473B2 (en) 2002-08-23 2003-08-22 Pyridyl substituted heterocycles useful for treating or preventing HCV infection

Publications (1)

Publication Number Publication Date
PL374536A1 true PL374536A1 (pl) 2005-10-31

Family

ID=31950772

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374536A PL374536A1 (pl) 2002-08-23 2003-08-22 Związki heterocykliczne podstawione pirydylem do stosowania w leczeniu lub zapobieganiu infekcji HCV

Country Status (15)

Country Link
US (3) US7157473B2 (pl)
EP (1) EP1530569A2 (pl)
JP (1) JP2006501312A (pl)
KR (1) KR20050033653A (pl)
AU (1) AU2003262831A1 (pl)
BR (1) BR0313755A (pl)
CA (1) CA2494164A1 (pl)
HR (1) HRP20050168A2 (pl)
IL (1) IL166639A0 (pl)
MX (1) MXPA05002082A (pl)
NO (1) NO20051404L (pl)
NZ (1) NZ537980A (pl)
PL (1) PL374536A1 (pl)
RS (1) RS20050175A (pl)
WO (1) WO2004018463A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2003262831A1 (en) * 2002-08-23 2004-03-11 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004099164A1 (en) * 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
EP1620412A2 (en) * 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Heterocyclic compounds and hydro isomers thereof
US7220745B2 (en) * 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
DK1658302T3 (da) 2003-07-25 2010-11-22 Idenix Pharmaceuticals Inc Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
US7410979B2 (en) * 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
EP1699446B1 (en) * 2003-12-19 2008-05-28 Rigel Pharmaceuticals, Inc. Compositions and methods for treating hepatitis c virus (hcv) infection
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
US20050239751A1 (en) * 2004-03-26 2005-10-27 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
WO2007027230A2 (en) 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
EP2954847B1 (en) * 2005-08-10 2019-02-06 C.R. Bard Inc. Single-insertion, multiple sample biopsy device with integrated markers
KR100890862B1 (ko) * 2005-11-07 2009-03-27 주식회사 엘지화학 유기 발광 소자 및 이의 제조 방법
TWI436767B (zh) * 2008-03-14 2014-05-11 Otsuka Pharma Co Ltd 基質金屬蛋白酶－２（ｍｍｐ－２）及／或基質金屬蛋白酶－９（ｍｍｐ－９）抑制劑
US8362020B2 (en) * 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN107709301B (zh) 2015-06-23 2021-06-22 橘生药品工业株式会社 吡唑衍生物或其药理学上可接受的盐
CN116535399B (zh) * 2022-01-25 2024-02-27 中国药科大学 3-羟基-5-(异噁唑-5-基)吡啶甲酰甘氨酸类化合物、制法、药物组合物和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852503A (en) * 1953-12-31 1958-09-16 American Cyanamid Co 2, 5-bis (p-aminophenyl) furan azo derivatives
BE581861A (pl) * 1958-08-20
US3335149A (en) * 1963-08-21 1967-08-08 Monsanto Co Thiazole diamines
FR1459375A (fr) 1965-10-20 1966-04-29 Westinghouse Electric Corp Copolymères linéaires oxadiazole-imide
SU508198A3 (ru) 1971-07-22 1976-03-25 Группо Лепетит С.П.А. (Фирма) Способ получени производных 1,2,4-триазола
DE2137719A1 (de) 1971-07-28 1973-02-08 Basf Ag Verfahren zur herstellung von aminobenzonitrilen
US3964896A (en) * 1971-08-09 1976-06-22 Uniroyal, Inc. Oxadiazole benzoic acid derivatives as herbicides
US3853893A (en) * 1973-04-02 1974-12-10 Squibb & Sons Inc Anthelmintic 5-(pyridyl)-3-(isothiocyanophenyl) oxadiazoles
DE2721955A1 (de) 1977-05-14 1978-11-23 Basf Ag Azofarbstoffe
DE3623302A1 (de) * 1985-11-09 1987-05-14 Bayer Ag Nicotinsaeurederivate
DE4016049A1 (de) * 1990-05-18 1991-11-21 Basf Ag 3-isoxazolylbenzylester, ihre herstellung und ihre verwendung
JPH04124178A (ja) 1990-09-12 1992-04-24 Sds Biotech Kk 複素環式化合物および該化合物を含有する除草剤
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE4137940A1 (de) * 1991-11-18 1993-05-19 Basf Ag 3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
ATE202701T1 (de) 1992-03-06 2001-07-15 Lica Pharmaceuticals As Behandlung und prophylaxe von durch parasiten oder bakterien verursachten erkrankungen
DE4210502A1 (de) 1992-03-31 1993-10-07 Bayer Ag Verwendung von 3-aminosubstituierten Isoxazolderivaten zur Bekämpfung von Endoparasiten, neue 3-aminosubstituierte Isoxazolderivate und Verfahren zu ihrer Herstellung
AU5891494A (en) 1993-01-29 1994-08-15 Nippon Soda Co., Ltd. Heterocyclic derivative
DE4408084A1 (de) 1994-03-10 1995-09-14 Hoechst Ag 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU3087195A (en) 1994-08-02 1996-03-04 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
KR19980701879A (ko) * 1995-02-02 1998-06-25 피터 기딩스 5-히드록시트립타민 수용체 길항제로서의 인돌 유도체
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
BR9808932A (pt) 1997-04-18 2000-08-01 Searle & Co Processo para prevenir um distúrbio cardiovascular relacionado com inflamação
US20020035156A1 (en) * 1997-04-18 2002-03-21 Barbara Roniker Combination therapy in the prevention of cardiovascular disorders
WO1999004390A1 (fr) 1997-07-17 1999-01-28 Sony Corporation Support d'enregistrement magnetique et dispositif d'enregistrement/de reproduction magnetique le comprenant
WO1999020309A1 (fr) 1997-10-22 1999-04-29 Eisai Co., Ltd. Agonistes de l'acide retinoique, agents preventifs et therapeutiques des nephrites
DE19860802A1 (de) 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
EP1180518B1 (en) 1999-04-23 2007-01-17 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
GB2351081A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Pharmaceutically active imidazoline compounds and analogues thereof
DE10032874A1 (de) 2000-07-06 2002-01-17 Bayer Ag Arzneimittelkombinationen gegen virale Erkrankungen
CA2404384A1 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
AU4890301A (en) * 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
AU2001288617A1 (en) 2000-09-05 2002-03-22 Neogenesis Pharmaceuticals Inc. Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
WO2002046186A1 (fr) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation
CA2433070A1 (en) 2001-01-13 2002-07-18 The University Of North Carolina At Chapel Hill Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (bvdv) infection and hepatitis c virus (hcv) infection
EE200300515A (et) * 2001-04-19 2004-02-16 Bayer Aktiengeshellschaft Arüülsulfoonamiidid kui viirusevastased ained
DE10148598A1 (de) * 2001-04-19 2002-10-24 Bayer Ag Neue Arylsulfonamide als antivirale Mittel
US7253190B2 (en) 2001-10-04 2007-08-07 Merck & Co., Inc. Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2003262831A1 (en) 2002-08-23 2004-03-11 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV

Also Published As

Publication number Publication date
RS20050175A (en) 2007-09-21
CA2494164A1 (en) 2004-03-04
WO2004018463A3 (en) 2004-05-06
US7332602B2 (en) 2008-02-19
MXPA05002082A (es) 2005-06-08
US7714137B2 (en) 2010-05-11
BR0313755A (pt) 2005-06-21
KR20050033653A (ko) 2005-04-12
HRP20050168A2 (en) 2005-10-31
US20080171871A1 (en) 2008-07-17
NZ537980A (en) 2007-08-31
US20040127497A1 (en) 2004-07-01
IL166639A0 (en) 2006-01-15
AU2003262831A1 (en) 2004-03-11
US20070155966A1 (en) 2007-07-05
WO2004018463A2 (en) 2004-03-04
JP2006501312A (ja) 2006-01-12
US7157473B2 (en) 2007-01-02
NO20051404L (no) 2005-05-10
EP1530569A2 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
IL166639A0 (en) Pyridyl substituted heterocycles useful for treating or preventing HCV infection
EP1451162A4 (en) SUBSTITUTED DIPHENYL HETEROCYCLES USEFUL FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
HK1080073A1 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
IL209352A0 (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
HK1091815A1 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA03006250A (es) Compuestos heterociclicos terapeuticos.
IL161401A0 (en) Organic waste treatment
IL164621A0 (en) Pestidical heterocycles
IL160208A0 (en) Amidine derivatives for treating amyloidosis
HK1074005A1 (en) Compositions and methods for treating or preventing pneumococcal infection
IL164352A0 (en) Methods for treating tweak-related conditions
GB0211257D0 (en) Novel heterocycles
IL159540A0 (en) Heterocyclic compounds as selective bacterial dhfr inhibitors and the uses thereof
AU2003249181A8 (en) Methods for treating or preventing ischemic injury
GB0120818D0 (en) Heterocyclic compounds
AU2003259202A8 (en) Compositions and methods for treating and preventing infection
FI20022150A0 (fi) Menetelmä kuonan käsittelemiseksi
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
ZA200501298B (en) Pyridyl substituted heterocycles useful for treating or preventing HCV infection
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2003254129A8 (en) Method and composition for treating and preventing hepatitis b infection and symptoms thereof
AU2003256678A8 (en) Method and composition for treating and preventing hepatitis c infection
PL1867644T3 (pl) Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
EP1589994A4 (en) PREPARATION AND METHOD FOR PREVENTING OR TREATING VIRAL INFECTION
FR2833294B1 (fr) Fermeture perfectionnee

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)